Title : Clinical pharmacology of sotagliflozin – Novel quality in treatment of heart failure
Abstract:
Heart failure is a serious clinical syndrome with symptoms and signs provoked by a structural and functional cardiac abnormality, and coupled with elevated natriuretic peptide levels and evident pulmonary or systemic congestion. Regardless of outstanding improvements in the management of heart failure over the past period, its prognosis is still poor with notable rates of mortality and hospitalization due to worsening of overall clinical presentation. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are relatively novel glucose-lowering drugs that furthermore promote weight loss and the reduction of blood pressure. Moreover, the data from ground-breaking trials clearly demonstrated that the beneficial effects of SGLT2 inhibitors extended to non-diabetic patients with chronic kidney disease and/or heart failure with reduced ejection fraction. Still, the risks vs. benefits in each patient should be carefully analyzed and weighed when making a prescribing decision due to known adverse drug reactions to SGLT2 inhibitors. Sotagliflozin is a recently registered SGLT2 inhibitor prescribed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. Given the previous facts, the main objectives of this presentation will be to clarify the pharmacological features of sotagliflozin, including pharmacodynamics, pharmacokinetics, indications, and contraindications for use, adverse drug reactions, as well as the most important drug interactions. This will provide a better understanding of this new-in-pharmacotherapy drug for heart failure, consequently helping clinicians in its suitable prescribing and adequate clinical use.
